Supernus Pharmaceuticals   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Rockville MD United States (2005)

Organization Overview

First Clinical Trial
2008
NCT00626236
First Marketed Drug
2005
apomorphine (apokyn)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MDD US | Supernus Pharmaceuticals | Supernus Pharmaceuticals, Inc. | SUPERNUS PHARMS

Active Ingredients

Marketed Drugs (5)

apomorphine (apokyn) (2004)

oxcarbazepine (trileptal) (2012)

safinamide (xadago) (2017)

topiramate (topamax) (2013)

viloxazine (2021)

Drugs in Phase 4 Trials (3)

Key: Supernus Pharmaceuticals (2) Acquired (1)

amantadine (symmetrel) (9 trials)

spn-538 (1 trial)

viloxazine (12 trials)

Drugs in Phase 3 Trials (5)

molindone (moban) (7 trials)

oxcarbazepine (trileptal) (3 trials)

rimabotulinumtoxinB (Myobloc) (2 trials)

spn-804 (1 trial)

spn-810 (2 trials)

Drugs in Phase 2 Trials (4)

Key: Supernus Pharmaceuticals (2) Acquired (2)

huperzine a (3 trials)

nv-5138 (2 trials)

oseltamivir (tamiflu) (1 trial)

topiramate (topamax) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 3)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Conduct Disorder (Phase 2)

Disease (Phase 4)

Epilepsies, Partial (Phase 3)

Epilepsy (Phase 3)

Headache (Phase 4)

Headache Disorders (Phase 4)

Hyperkinesis (Phase 3)

Impulsive Behavior (Phase 2)

Migraine Disorders (Phase 4)

Seizures (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 45
  • # of Trial APIs: 12